Day: September 27, 2024

VANCOUVER, British Columbia, Sept. 27, 2024 (GLOBE NEWSWIRE) — Global Uranium Corp. (CSE: GURN | OTC PINK: GURFF | FRA: Q3J) (the “Company“) announces that Mr. Eli Dusenbury has stepped down as Chief Financial Officer of the Company. To fill the vacancy created by Mr. Dusenbury’s resignation, the Company has appointed Mr. Nico Mah to serve as the Company’s Chief Financial Officer. Mr. Mah is a Chartered Professional Accountant and has over eight years of experience in auditing and public accountancy, articling and working up to manager at PricewaterhouseCoopers LLP from September 2015 to January 2023. Mr. Mah is the managing director of GKM Consulting Inc., a private accounting consulting firm. He holds a Bachelor of Commerce degree, majoring in Accounting, from the University of Calgary and a CPA designation in Alberta,...

VANCOUVER, British Columbia, Sept. 27, 2024 (GLOBE NEWSWIRE) — HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF) (“HYTN” or “the Company”), a pharmaceutical company specializing in the development, formulation, and manufacturing of psychoactive and psychotropic compounds, including cannabinoids and psilocybin, is pleased to announce, further to its news release dated July 19, 2024, that it has filed a Business Acquisition Report (BAR) in respect of its acquisition of Prism Scientific Labs Inc. The BAR may be found under the Company’s profile on SEDAR+ (www.sedarplus.ca). About HYTN Innovations Inc. HYTN Innovations Inc. is a pharmaceutical company that specializes in the formulation, manufacturing, marketing, and sale of products containing psychoactive and psychotropic compounds, including cannabis-derived cannabinoids...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Sept. 27, 2024 (GLOBE NEWSWIRE) — Hampton Financial Corporation (“Hampton” or the “Company”, TSXV:HFC) is pleased to announce the closing of a non-brokered private placement of unsecured convertible debentures (the “Debentures”) in the principal amount of $500,000. The $500,000 principal amount of Debentures will mature five (5) years and one day after the issue date (the “Maturity Date”) and will bear interest at the rate of 11.0% per annum, payable quarterly in arrears on the last day of March, June, September and December in each year until the Maturity Date. The first interest payment will be made at the end of the first calendar quarter following the closing date (the “Initial Interest Payment Date”) and will consist of interest...

– Acoramidis treatment led to a highly significant reduction in all-cause mortality (ACM) and recurrent cardiovascular-related hospitalizations (CVH) at Month 30 compared with placebo – Additionally, results from a Phase 3 trial in adults with ATTR-CM conducted in Japan were presented, with no ACM events reported over the 30 month treatment period in participants administered acoramidis – Greater transthyretin (TTR) stabilization has been associated with improved clinical outcomes for patients, and in ATTRibute-CM, acoramidis, a near-complete stabilizer of TTR, demonstrated a significant impact on mortality, hospitalizations, and quality of life including: – An early and sustained improvement relative to placebo in time to first event (CVH or ACM) with a separation of event rates starting at Month 3– A 42%...

VANCOUVER, British Columbia, Sept. 27, 2024 (GLOBE NEWSWIRE) — CMC Metals Ltd. (TSX-V: CMB) (Frankfurt:ZM5P) (“CMC” or the “Company”) announces that the TSX Venture Exchange (the “TSXV”) has approved the Company’s request to extend the expiry date of 2,161,557 share purchase warrants, originally granted September 27, 2022 to September 27, 2025, and 1,942,014 share purchase warrants, originally granted October 12, 2022, to October 13, 2025. The request to amend the exercise price from $0.20 to $0.07 remains subject to TSXV approval and the consent of the Warrant holders (the “Amended Warrants”). Each Amended Warrant is exercisable into one (1) common share of the Company and will be subject to an acceleration clause such that the exercise period of the Warrants will be reduced to 30 days, if for any ten consecutive trading days...

BOSTON, Sept. 27, 2024 (GLOBE NEWSWIRE) — Worlds Inc. (Worlds) (OTCQB: WDDD) announces today that it is parting ways with Jordan Freeman. Mr. Freeman had been a director of Worlds since his appointment on May 14, 2024. On August 27, 2024, Worlds announced it had closed on an agreement to license the ZOOM Platform and certain other intellectual properties. That release was deployed prematurely, prior to the execution of such agreement and closure of the same. Subsequent to the announcement, Mr. Freeman expressed his desire to resign. Accordingly, the parties have agreed to terminate further discussions and Mr. Freeman has resigned from Worlds’ board of directors. Thomas Kidrin, Worlds’ CEO, stated, “I thank Jordan for his time as a director and I wish him continued success in his business ventures.” Contacts:julie@accentuatepr.com About...

Nashville, TN, Sept. 27, 2024 (GLOBE NEWSWIRE) — American Rebel Holdings, Inc. (NASDAQ: AREB) — America’s Patriotic Brand (the “Company”), today announced that it will effect a reverse stock split of its outstanding shares of common stock, par value $0.001 per share (the “Common Stock”), at a ratio of 1-for-9, to be effective as of 12:00 a.m. Eastern Time on October 2, 2024. The Company’s Common Stock will begin trading on a reverse stock split-adjusted basis at the opening of The Nasdaq Capital Market (“Nasdaq”) on Wednesday, October 2, 2024. Following the reverse stock split, the Common Stock will continue to trade on Nasdaq under the symbol “AREB” with the new CUSIP number, 02919L505. The reverse stock split is intended for the Company to regain compliance with the minimum bid price requirement of $1.00 per share of common stock...

Landmark CARTITUDE-4 study results show CARVYKTI® reduced the risk of death by 45 percent after three-year follow-up Late-breaking data featured in an oral presentation at the 21st International Myeloma Society Annual MeetingSOMERSET, N.J., Sept. 27, 2024 (GLOBE NEWSWIRE) — Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced late-breaking three-year follow-up data from the Phase 3 CARTITUDE-4 study that shows a single infusion of CARVYKTI® (ciltacabtagene autoleucel) significantly extended overall survival (OS) in patients with relapsed or lenalidomide-refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor (PI), and an immunomodulatory agent (IMiD), reducing the risk of death by 45 percent versus standard therapies...